Table 1.
Genomics and the healthcare continuum4
Healthcare continuum | Genomic application example | Clinical application example |
---|---|---|
Preconception/prenatal | Germline genetic testing for recessive conditions | Preconception testing for carrier status in prospective parents for genetic variants associated with recessive conditions, such as sickle cell disease, cystic fibrosis, and Tay Sachs disease18 |
Cell-free fetal DNA from maternal plasma | Less invasive strategy compared with amniocentesis for assessing fetal genomic variations that have health implications such as fetal aneuploidy19 | |
Newborn screening | State-mandated newborn screening; not all recommended screening tests are genetic tests, but they screen for indications of the need for further genetic evaluation | Approximately 4 million newborns screened annually using dried blood spot cards for conditions such as immunodeficiency disorder and congenital heart disease20 |
Disease susceptibility | Germline genetic testing | Inherited cancer syndromes, such as hereditary breast ovarian syndrome, associated with mutations in BRCA1 and BRCA221 |
Familial hypercholesterolemia associated with mutations in LDLR, APOB, and PCSK922 | ||
Screening and diagnosis | Stool DNA testing | FDA-approved test that can be used for screening purposes instead of colonoscopy23 |
Prognosis and therapeutic decisions | Targeted therapies | Therapy based on tumor genomic variation, such as epidermal growth factor receptor somatic mutation in non–small cell lung cancer and tyrosine kinase inhibitors24 |
Tumor profiling | Basket trials, such as the Molecular Analysis for Therapy Choice, or NCI-MATCH, designed to identify somatic mutations/amplifications/translocations in patient tumor samples and assign patients to agents/regimens based on tumor genomics and not histology25 | |
Pharmacogenomics | Individuals who carry HLA-B*57:01 have an increased risk of hypersensitivity to the antiretroviral drug abacavir26 | |
Monitoring disease burden and recurrence | Pharmacogenomics | Symptom management such as pain control; CYP2D6 to determine whether an individual can convert codeine into the active metabolite morphine26 |